Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Seeks Early Gardasil Male Recommendation, But FDA, CDC Are Wary

Executive Summary

Merck's presentation of data on the use of Gardasil in males at FDA's recent Vaccines & Related Biological Products Advisory Committee meeting suggests the firm is positioning the product for a broader recommendation from the Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices

You may also be interested in...



Cervarix, Gardasil Set For FDA Advisory Committee Review

GlaxoSmithKline knew it was in for scrutiny of its novel AS04 adjuvant, but review of Merck's application to make Gardasil gender-neutral could offer backdoor to re-examine the HPV vaccine's safety record.

Gardasil Reimbursement Issues To Be Resolved In Early 2007, Merck Says

Merck expects reimbursement issues for its human papillomavirus vaccine Gardasil to be resolved by early 2007, Merck Vaccines President Margaret McGlynn said Dec. 12

Gardasil Reimbursement Issues To Be Resolved In Early 2007, Merck Says

Merck expects reimbursement issues for its human papillomavirus vaccine Gardasil to be resolved by early 2007, Merck Vaccines President Margaret McGlynn said Dec. 12

Related Content

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel